Hikma Pharmaceuticals (HIK)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 19.2 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 3.66 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | $m | |||||||||
| Operating Profit | $m | |||||||||
| Net Profit | $m | |||||||||
| EPS Reported | $ | |||||||||
| EPS Normalised | $ | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | $ | |||||||||
| Capex ps | $ | |||||||||
| Free Cashflow ps | $ | |||||||||
| Last ex-div: 17th Apr, paid: 23rd May more... Dividends | ||||||||||
| Dividend ps | $ | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | $m | |||||||||
| Working Capital | $m | |||||||||
| Net Fixed Assets | $m | |||||||||
| Net Debt | $m | |||||||||
| Book Value | $m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | $ | +11.5% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, Hikma Pharmaceuticals Plc revenues increased 21% to $1.11B. Net income increased 25% to $100.3M. Revenues reflect Injectable Pharmaceuticals segment increase of 49% to $470M, Branded Pharmaceuticals segment increase of 20% to $528.9M, Others segment increase of 10% to $6.2M, Middle East and North Africa segment increase of 22% to $619.2M, United States segment increase of 26% to $399.9M. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 2 | 0 | 1 | 4 | 4 |
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates in three business segments: Branded, Injectables, and Generics. The majority of its operations are in the Middle East and North Africa region, the United States and Europe. The Company’s operations span over 45 countries and focuses on a range of therapeutic areas. The Company’s other businesses primarily consists of Arab Medical Containers Ltd, a manufacturer of pharmaceutical packaging; and International Pharmaceutical Research Center Ltd, which conducts bio-equivalency studies, and the chemicals division of Hikma Pharmaceuticals Ltd
Directors: Said Darwazah (CEO) 54, Mazen Darwazah (Vice Chmn.) 54, Khalid Nabilsi (CFO) , Bassam Kanaan (Corp. Exec.) 47, Michael Raya (Corp. Exec.) , Ibrahim Jalal (Sr. VP) , Majda Labadi (VP) , Susan Ringdal (VP) , Riad Mishlawi (VP) , Fadi Nassar (VP) ,
No. of Employees: 6,649 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 197,484,369 |
| Free Float | 129.7m (65.7%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE 350 Act , FTSE Lower Yield , FTSE 250 Mid , FT350 Phar & Bio , |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | , LONDON, W1S 1HW, United Kingdom |
| Web | http://www.hikma.com/ |
| Phone | +44 20 73992760 |
| Contact | Susan Ringdal (Vice President - Investor Relations and Group Goal Compliance,Investor Relations Director) |
| Registrar | Capita Registrars (Kent) |
| Auditors | Deloitte LLP |
| 3rd Jun | Total Voting Rights |
| 28th May | Holding(s) in Company |
| 23rd May | Director/PDMR Shareholding |
| 21st May | Director/PDMR Shareholding |
| 20th May | Director/PDMR Shareholding |
| 16th May | Result of AGM |
Recent ↓
